Artbio

ARTBIO AS is a Norwegian biopharmaceutical company developing alpha radioligand therapies (ART) for cancer. Its lead program, AB001 (212Pb-NG001), is in prostate cancer and has entered first-in-human studies. Further programs cover other solid tumours and are at non-clinical or discovery stage. The company also works on isotope production, using its AlphaDirect approach with the Pb212 isotope.

The company's customers are cancer patients, and it works with partners in discovery and development and in manufacturing. Its board includes representatives of venture investors, among them Third Rock Ventures, F-Prime Capital, Omega Funds, Sofinnova Investments and B Capital.

ARTBIO was founded in 2018 and is headquartered in Oslo, Norway. Its scientific roots are at the University of Oslo and Norway's Radium Hospital, and its scientific co-founders, Roy Larsen and Øyvind Bruland, invented Xofigo. In April 2026 the company announced a voluntary clinical hold of the ARTISAN trial of AB001, and in July 2026 it appointed Jonathan Freeman as interim chief executive officer.

Product: Alpha radioligand therapies (ART) for cancer, led by AB001 (212Pb-NG001) for prostate cancer, plus AlphaDirect isotope production.